102 related articles for article (PubMed ID: 9108200)
1. The oncoproteins c-erb-B2, c-fos and the tumour suppressor protein p53 in human embryos and fetuses.
Miosge N; Schneider W; Götz W; Herken R
Anat Embryol (Berl); 1997 Apr; 195(4):345-52. PubMed ID: 9108200
[TBL] [Abstract][Full Text] [Related]
2. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Volm M; Efferth T; Mattern J
Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma.
Cherchi PL; Marras V; Capobianco G; Ambrosini G; Piga MD; Fadda GM; Rosas N; Dessole S
Eur J Gynaecol Oncol; 2001; 22(6):451-3. PubMed ID: 11874080
[TBL] [Abstract][Full Text] [Related]
4. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
5. [Expression of PCNA, C-fos and Bax proteins in human embryonic tongue tissues].
Liu XH; Zhang Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 42(5):517-22. PubMed ID: 24167132
[TBL] [Abstract][Full Text] [Related]
6. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas.
Kim YW; Huh SH; Park YK; Yoon TY; Lee SM; Hong SH
Oncol Rep; 2001; 8(5):1127-32. PubMed ID: 11496329
[TBL] [Abstract][Full Text] [Related]
7. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time.
Heinze T; Jonas S; Kärsten A; Neuhaus P
Anticancer Res; 1999; 19(4A):2501-3. PubMed ID: 10470182
[TBL] [Abstract][Full Text] [Related]
8. Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma.
Midulla C; Giovagnoli MR; Valli C; Vecchione A
Anal Quant Cytol Histol; 1995 Jun; 17(3):157-62. PubMed ID: 7546049
[TBL] [Abstract][Full Text] [Related]
9. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas.
Botelho CH; Magalhães AV; Mello PA; Schmitt FC; Casulari LA
Arq Neuropsiquiatr; 2006 Mar; 64(1):60-6. PubMed ID: 16622555
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic endocrine tumors-c-erb B2 (Her-2/neu), bcl-2, and p-53 immunohistochemical testing and their value in assessing prognosis.
Proca DM; Frankel WL
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):44-7. PubMed ID: 18091321
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas.
Magrisso IJ; Richmond RE; Carter JH; Pross CB; Gilfillen RA; Carter HW
Lab Invest; 1993 Dec; 69(6):674-81. PubMed ID: 8264230
[TBL] [Abstract][Full Text] [Related]
13. Serum and tissue c-erb B2, bcl-2, and mutant p53 oncoprotein levels in nasopharyngeal cancer.
Yazici H; Altun M; Hafiz G; Dalay N
Cancer Invest; 2001; 19(8):773-8. PubMed ID: 11768029
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2.
Sakr SA; Mahran HA; Fahmy AM; El-Kholy MA; Meawad M
Biomed Pharmacother; 2015 Dec; 76():73-81. PubMed ID: 26653553
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
[TBL] [Abstract][Full Text] [Related]
16. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.
Duhaylongsod FG; Gottfried MR; Iglehart JD; Vaughn AL; Wolfe WG
Ann Surg; 1995 Jun; 221(6):677-83; discussion 683-4. PubMed ID: 7794072
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormones in tissues from human embryos and fetuses.
Costa A; Arisio R; Benedetto C; Bertino E; Fabris C; Giraudi G; Marozio L; Maulà V; Pagliano M; Testori O
J Endocrinol Invest; 1991; 14(7):559-68. PubMed ID: 1940061
[TBL] [Abstract][Full Text] [Related]
18. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
19. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
